Medical Oncology

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


972 publications

... | 2022 | 2021 | ...
2022
Organoids: A New Chapter in Sarcoma Diagnosis and Treatment.
Psilopatis I., Kokkali S., Palamaris K., Digklia A., Vrettou K., Theocharis S., 2022/09/24. International journal of molecular sciences, 23 (19) p. 11271. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E6378E1D11BD]
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto P.A., Agarwala S.S., Blank C., Caracò C., Carvajal R.D., Ernstoff M.S., Ferrone S., Fox B.A., Gajewski T.F., Garbe C. et al., 2022/09/04. Journal of translational medicine, 20 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E798A46CDF9]
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S., Dziadziuszko R., Morabito A., Felip E., Gadgeel S.M., Cheema P., Cobo M., Andric Z., Barrios C.H., Yamaguchi M. et al., 2022/09. Nature medicine, 28 (9) pp. 1831-1839. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D64BF6CDC58E]
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
Adamina M., Warlaumont M., Berger M.D., Däster S., Delaloye R., Digklia A., Gloor B., Fritsch R., Koeberle D., Koessler T. et al., 2022/09/01. Cancers, 14 (17) p. 4275. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62CF2A596AB9]
 
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group.
Sclafani F., Fontana E., Wyrwicz L., Wagner A.D., Valle J.W., Smyth E., Peeters M., Obermannova R., Neuzillet C., Lutz M.P. et al., 2022/09. Clinical colorectal cancer, 21 (3) pp. 188-197. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_700C97DDB27C]
 
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F., Reymen B., Peters S., Van Mol P., Wauters E., Vansteenkiste J., De Ruysscher D., Hendriks LEL, 2022/09. Annals of oncology, 33 (9) pp. 893-908. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2C9FA7FE4F90]
 
Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.
Quaas A., Biesma H.D., Wagner A.D., Verheij M., van Berge Henegouwen M.I., Schoemig-Markiefka B., Pamuk A., Zander T., Siemanowski J., Sikorska K. et al., 2022/09. European journal of cancer, 173 pp. 95-104. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3F864F08541F]
 
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Le Rhun E., Oppong F.B., Vanlancker M., Stupp R., Nabors B., Chinot O., Wick W., Preusser M., Gorlia T., Weller M., 2022/09/01. Neuro-oncology, 24 (9) pp. 1533-1545. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C41F4087F4FB]
Steering decision making by terminology: oligometastatic versus argometastatic.
Szturz P., Vermorken J.B., 2022/09. British journal of cancer, 127 (4) pp. 587-591. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4166A465DB55]
Conceptualization and content validation of the MEDication literacy assessment of geriatric patients and informal caregivers (MED-fLAG).
Gentizon J., Fleury M., Pilet E., Büla C., Mabire C., 2022/08/19. Journal of patient-reported outcomes, 6 (1) p. 87. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4A8739AC0995]
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.
Wysocki O., Zhou C., Rogado J., Huddar P., Shotton R., Tivey A., Albiges L., Angelakas A., Arnold D., Aung T. et al., 2022/08/16. Cancers, 14 (16) p. 3931. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB438C1281CE]
Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors
Hibar Derrek P., Demetri George D., Peters Solange, Davies Jessica, Humblet Olivier, Maund Sophia L., Perez Laura, 2022/08/08. PLOS ONE, 17 (8) pp. e0270571.
[URN][DOI][Pmid][serval:BIB_A5401C2FA2EC]
The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal Cancer-A Swiss Perspective in the Context of an International Viewpoint.
Siebenhüner A.R., Lo Presti G., Helbling D., Szturz P., Astaras C., Buccella Y., De Dosso S., 2022/08/06. Current oncology, 29 (8) pp. 5604-5615. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB0867D1DFC7]
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
James N.D., Clarke N.W., Cook A., Ali A., Hoyle A.P., Attard G., Brawley C.D., Chowdhury S., Cross W.R., Dearnaley D.P. et al., 2022/08/01. International journal of cancer, 151 (3) pp. 422-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A1169D8AF655]
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.
Bestvina C.M., Whisenant J.G., Torri V., Cortellini A., Wakelee H., Peters S., Roca E., De Toma A., Hirsch F.R., Mamdani H. et al., 2022/08. JTO clinical and research reports, 3 (8) p. 100335. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EBBB31952F9C]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.
Kanesvaran R., Castro E., Wong A., Fizazi K., Chua MLK, Zhu Y., Malhotra H., Miura Y., Lee J.L., Chong FLT et al., 2022/08. ESMO open, 7 (4) p. 100518. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EA8968ED0707]
Inflammatory Myofibroblastic Tumour: State of the Art.
Gros L., Dei Tos A.P., Jones R.L., Digklia A., 2022/07/27. Cancers, 14 (15) p. 3662. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BF48E08DCCE9]
 
Structure-based prediction of BRAF mutation classes using machine-learning approaches.
Krebs F.S., Britschgi C., Pradervand S., Achermann R., Tsantoulis P., Haefliger S., Wicki A., Michielin O., Zoete V., 2022/07/22. Scientific reports, 12 (1) p. 12528. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5CB3AA02B4B8]
Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study.
Hofheinz R.D., Anchisi S., Grünberger B., Derigs H.G., Zahn M.O., Geffriaud-Ricouard C., Gueldner M., Windemuth-Kieselbach C., Pederiva S., Bohanes P. et al., 2022/07/20. Cancers, 14 (14) p. 3522. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8CB2320EFA26]
 
Setting the Benchmark for KRAS G12C -Mutated NSCLC.
Passaro A., Peters S., 2022/07/14. The New England journal of medicine, 387 (2) pp. 180-183. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0707DF81346A]
 
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Luigi Banna G., Addeo A., Zygoura P., Tsourti Z., Popat S., Curioni-Fontecedro A., Nadal E., Shah R., Pope A., Fisher P. et al., 2022/07. Lung cancer, 169 pp. 77-83. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8EE8C213DF72]
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S., Paz-Ares L., Herbst R.S., Reck M., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004863. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_94A63A329C06]
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I., Zakria D., Ahmed T., Trojanello C., Dimitriou F., Allayous C., Gerard C., Zimmer L., Lo S., Michielin O. et al., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004610. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D204CE09BBCB]
 
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
Bhave P., Ahmed T., Lo S.N., Shoushtari A., Zaremba A., Versluis J.M., Mangana J., Weichenthal M., Si L., Lesimple T. et al., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004668. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B4F52EB38286]
 
Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
Zeitlberger A.M., Putora P.M., Hofer S., Schucht P., Migliorini D., Hottinger A.F., Roelcke U., Läubli H., Spina P., Bozinov O. et al., 2022/07. Journal of neuro-oncology, 158 (3) pp. 359-367. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8E6C586A4C96]
Cancers professionnels : l’essentiel pour le médecin au cabinet [Occupational cancers: essentials for the general practioners]
Krief P., Cohidon C., Turcu V., Rinaldo M., Kamara M., Koller M., Zyska Cherix A., Senn N., Peters S., 2022/06/29. Revue medicale suisse, 18 (788) pp. 1313-1321. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A5BC2572EB3B]
Traitement de la douleur cancéreuse : au-delà des approches médicamenteuses conventionnelles [Cancer pain therapy: beyond conventional pharmacological approaches]
Maseri A., Montavon G., Ungarelli-McEvoy C.G., Suter M.R., Berna C., 2022/06/22. Revue medicale suisse, 18 (787) pp. 1264-1267. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5F6F7059F331]
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
Courlet P., Cardoso E., Bandiera C., Stravodimou A., Zurcher J.P., Chtioui H., Locatelli I., Decosterd L.A., Darnaud L., Blanchet B. et al., 2022/06/21. Pharmaceutics, 14 (7) p. 1317. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E7FBC59504B2]
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease.
Herrera-Gómez R.G., Grecea M., Gallois C., Boige V., Pautier P., Pistilli B., Planchard D., Malka D., Ducreux M., Mir O., 2022/06/13. Cancers, 14 (12) p. 2914. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_02DA89DB65E7]
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor.
Scabia V., Ayyanan A., De Martino F., Agnoletto A., Battista L., Laszlo C., Treboux A., Zaman K., Stravodimou A., Jallut D. et al., 2022/06/06. Nature communications, 13 (1) p. 3127. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BED35CC8098E]
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.
Razis E., Escudero M.J., Palmieri C., Mueller V., Bartsch R., Rossi G., Gampenrieder S.P., Kolberg H.C., Zdenkowski N., Pavic M. et al., 2022/06. ESMO open, 7 (3) p. 100483. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_203D7B0D2C78]
 
Author Correction: Clinical relevance of tumour-associated macrophages.
Pittet M.J., Michielin O., Migliorini D., 2022/06..
[DOI][WoS][Pmid][serval:BIB_60BF1DA61627]
 
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].
König D., Schär S., Vuong D., Guckenberger M., Furrer K., Opitz I., Weder W., Rothschild S.I., Ochsenbein A., Zippelius A. et al., 2022/06. ESMO open, 7 (3) p. 100494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_74C3D3CD6DB5]
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
Castelo-Branco L., Tsourti Z., Gennatas S., Rogado J., Sekacheva M., Viñal D., Lee R., Croitoru A., Vitorino M., Khallaf S. et al., 2022/06. ESMO open, 7 (3) p. 100499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_880DB2367FE3]
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni U., Soo R.A., Peters S., Tsourti Z., Zygoura P., Vervita K., Han J.Y., De Castro J., Coate L., Früh M. et al., 2022/06. ESMO open, 7 (3) p. 100507. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EABD7EDC5C76]
Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology.
Özdemir B.C., Gerard C.L., Espinosa da Silva C., 2022/06/01. Endocrinology, 163 (6) pp. bqac058. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FFB3F9CC400F]
Effets indésirables des nouvelles thérapies du cancer du sein : quand faut-il réagir ? [Adverse effects of new breast cancer therapies : when to react ?]
Dris N., Meyer M.L., Flores Torres C., Curtit E., Zurcher J.P., Stravodimou A., Zaman K., 2022/05/18. Revue medicale suisse, 18 (782) pp. 997-1001. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_6573A443A776]
Prise en charge des métastases cérébrales en 2022 [Management of brain metastases in 2022]
Schiappacasse L., Kinj R., De Micheli R., Mederos N., Tuleasca C., Cossu G., Dunet V., Levivier M., Bourhis J., Hottinger A.F., 2022/05/18. Revue medicale suisse, 18 (782) pp. 976-983. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C341F49A8ECA]
Thérapies ciblées et carcinomes non à petites cellules : nouveautés [Targeted therapies and non-small cell carcinomas : novelties]
Stauber R., Gro S L., Nguyen-Ngoc T., Mederos N., Bouchaab H., Peters S., Abdelhamid K., 2022/05/18. Revue medicale suisse, 18 (782) pp. 970-975. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FB698780FC89]
Traitements intrapéritonéaux de la carcinose ovarienne : proposition d’algorithmes décisionnels [Intraperitoneal therapy for carcinomatosis in ovarian cancer: proposed treatment algorithm]
Undurraga M., Mathevet P., Hubner M., Buchs N.C., Warlaumont M., Sarivalasis A., Diciolla A., Lang N., Koessler T., Digklia A. et al., 2022/05/18. Revue medicale suisse, 18 (782) pp. 990-996. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_521D9B8BA734]
Une période de terreur et de défis : quand verrons-nous ce monde meilleur ?
Dietrich P.Y., Aapro M., Peters S., 2022/05/18. Revue medicale suisse, 18 (782) pp. 967-968. Peer-reviewed.
[URN][DOI][serval:BIB_146AF71DA32B]
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
Homicsko K., Dummer R., Hoeller C., Wolchok J.D., Hodi F.S., Larkin J., Ascierto P.A., Atkinson V., Robert C., Postow M.A. et al., 2022/05/05. Cancers, 14 (9) p. 2300. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4D579FC357B1]
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Dziadziuszko R., Peters S., Mok T., Camidge D.R., Gadgeel S.M., Ou S.I., Konopa K., Noé J., Nowicka M., Bordogna W. et al., 2022/05/02. Clinical cancer research, 28 (9) pp. 1800-1808. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_67ED3D3777DA]
 
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Digklia A., Coukos G., Homicsko K., 2022/05/02. Clinical cancer research, 28 (9) pp. 1745-1747. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0CAC463D4200]
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.
Whisenant J.G., Baena J., Cortellini A., Huang L.C., Lo Russo G., Porcu L., Wong S.K., Bestvina C.M., Hellmann M.D., Roca E. et al., 2022/05. Journal of thoracic oncology, 17 (5) pp. 661-674. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A000CE08497]
 
Acute ischemic stroke in patients with newly diagnosed versus known active cancer: characteristics, mechanisms, and recurrences
Costamagna Gianluca, Hottinger Andreas, Milionis Haralampos, Salerno Alexander, Strambo Davide, Navi Babak, Michel Patrik (eds.), 2022/05., European Stroke Organisation Conference, 4-6 May 2022, Lyon, France, 7 1_suppl, European Stroke Journal .
[DOI][WoS][serval:BIB_14152F80D5B8]
 
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D., Ramalingam S., Urbanic J., Gerber D.E., Tan DSW, Cai J., Li A., Peters S., 2022/05. Clinical lung cancer, 23 (3) pp. e264-e268. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_800C38154E47]
 
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Pérol M., Felip E., Dafni U., Polito L., Pal N., Tsourti Z., Ton TGN, Merritt D., Morris S., Stahel R. et al., 2022/05. Annals of oncology, 33 (5) pp. 511-521. Peer-reviewed.
[DOI][Pmid][serval:BIB_179CC1EDD39A]
 
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
Passaro A., Leighl N., Blackhall F., Popat S., Kerr K., Ahn M.J., Arcila M.E., Arrieta O., Planchard D., de Marinis F. et al., 2022/05. Annals of oncology, 33 (5) pp. 466-487. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3A6B7045371A]
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee R.J., Wysocki O., Zhou C., Shotton R., Tivey A., Lever L., Woodcock J., Albiges L., Angelakas A., Arnold D. et al., 2022/05. JCO clinical cancer informatics, 6 pp. e2100177. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5BE25E8275C]
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A., Antonia S., Bautista Y., Grossi F., Kowalski D., Zalcman G., Nowak A.K., Fujimoto N., Peters S., Tsao A.S. et al., 2022/05. Lung cancer, 167 pp. 8-16. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A48722CEDE6A]
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S., Scherpereel A., Cornelissen R., Oulkhouir Y., Greillier L., Kaplan M.A., Talbot T., Monnet I., Hiret S., Baas P. et al., 2022/05. Annals of oncology, 33 (5) pp. 488-499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_78CBA16F62E5]
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M., Suffiotti M., Pellaton C., Bouchaab H., Cairoli A., Salvadé V., Stevenel C., Hottinger R., Pythoud C., Coutechier L. et al., 2022/05/01. JAMA oncology, 8 (5) pp. e220446. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8956034C5615]
 
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K., Foulon S., Carles J., Roubaud G., McDermott R., Fléchon A., Tombal B., Supiot S., Berthold D., Ronchin P. et al., 2022/04/30. Lancet, 399 (10336) pp. 1695-1707. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B29C8E2B2F13]
EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma.
Möller E., Praz V., Rajendran S., Dong R., Cauderay A., Xing Y.H., Lee L., Fusco C., Broye L.C., Cironi L. et al., 2022/04/27. Nature communications, 13 (1) p. 2267. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_73886BC749BC]
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Joerger M., Metaxas Y., Zaman K., Michielin O., Mach N., Bettini A., Schmitt A.M., Cantoni N., Caspar C.B., Stettler S. et al., 2022/04/27. Cancers, 14 (9) p. 2191. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D0043AF001BA]
ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.
Koessler T., Alsina M., Arnold D., Ben-Aharon I., Collienne M., Lutz M.P., Neuzillet C., Obermannova R., Peeters M., Sclafani F. et al., 2022/04. ESMO open, 7 (2) p. 100392. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_851DF44B5BE1]
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report.
Ball M., Christopoulos P., Kirchner M., Allgäuer M., Brandt R., Winter H., Heußel C.P., Herth F., Fröhling S., Savai R. et al., 2022/04. Cold Spring Harbor molecular case studies, 8 (3) pp. a006156. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_1A3C674BFA41]
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
König D., Schär S., Vuong D., Guckenberger M., Furrer K., Opitz I., Weder W., Rothschild S.I., Ochsenbein A., Zippelius A. et al., 2022/04. ESMO open, 7 (2) p. 100455. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3670D738F077]
 
The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns.
Glas M., Ballo M.T., Bomzon Z., Urman N., Levi S., Lavy-Shahaf G., Jeyapalan S., Sio T.T., DeRose P.M., Misch M. et al., 2022/04/01. International journal of radiation oncology, biology, physics, 112 (5) pp. 1269-1278. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4C099FBD4AC4]
Verzögerte Diagnose eines Lungenkarzinoms, das sich als choroidale Metastase in einem COVID-19-Patienten präsentierte und am Anfang mit Osimertinib behandelt wurde [Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib]
Haeller C.N., Khamsy L., Kloepper J., Schiappacasse L., Bouchaab H., Peters S., Schalenbourg A., 2022/04. Klinische Monatsblatter fur Augenheilkunde, 239 (4) pp. 586-589. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B66EE0FBC45A]
 
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Paz-Ares L., O'Brien M.E.R., Mauer M., Dafni U., Oselin K., Havel L., Esteban Gonzalez E., Isla D., Martinez-Marti A., Faehling M. et al., 2022/04. Annals of Oncology, 33 (4) pp. 451-453.
[DOI][WoS][serval:BIB_5EB0E80DC3F2]
Implication des patients dans la recherche en oncologie - Développement d’un cadre de référence en Suisse romande [Patient involvement in oncology research - Development of a reference framework in French-speaking Switzerland]
Colomer-Lahiguera S., Corbière T., Reeb-Landry F., Ninane F., Addeo A., Eicher M., 2022/03/30. Revue medicale suisse, 18 (775) pp. 621-625. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_4FBDE0B1B82A]
 
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
Fu Julie, Reid Sonya A., French Benjamin, Hennessy Cassandra, Hwang Clara, Gatson Na Tosha, Duma Narjust, Mishra Sanjay, Nguyen Ryan, Hawley Jessica E. et al., 2022/03/28. JAMA Network Open, 5 (3) pp. e224304.
[DOI][WoS][Pmid][serval:BIB_4468EB901809]
 
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Mohile Nimish A, Messersmith Hans, Gatson Na Tosha N, Hottinger Andreas F, Lassman Andrew B, Morton Jordan, Ney Douglas, Nghiemphu Phioanh Leia, Olar Adriana, Olson Jeffery et al., 2022/03/12. Neuro-Oncology, 24 (3) pp. 358-383.
[DOI][WoS][serval:BIB_1B20FB31D2FA]
COVID-19 vaccination and breakthrough infections in patients with cancer
Schmidt A.L., Labaki C., Hsu C.-Y., Bakouny Z., Balanchivadze N., Berg S.A., Blau S., Daher A., El Zarif T., Friese C.R. et al., 2022/03. Annals of Oncology, 33 (3) pp. 340-346.
[URN][DOI][WoS][Pmid][serval:BIB_C847E8167D45]
 
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
Kroese T.E., van Hillegersberg R., Schoppmann S., Deseyne PRAJ, Nafteux P., Obermannova R., Nordsmark M., Pfeiffer P., Hawkins M.A., Smyth E. et al., 2022/03. European journal of cancer, 164 pp. 18-29. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A66490D09189]
 
Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis.
Tan A.C., Tan S.H., Zhou S., Peters S., Curigliano G., Tan DSW, 2022/03. Cancer treatment reviews, 104 p. 102354. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BFD000998B6C]
 
Process mining for healthcare: Characteristics and challenges.
Munoz-Gama J., Martin N., Fernandez-Llatas C., Johnson O.A., Sepúlveda M., Helm E., Galvez-Yanjari V., Rojas E., Martinez-Millana A., Aloini D. et al., 2022/03. Journal of biomedical informatics, 127 p. 103994. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C95384A66C26]
Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper.
Raoul J.L., Edeline J., Simmet V., Moreau-Bachelard C., Gilabert M., Frénel J.S., 2022/02/24. Cancers, 14 (5) p. 1156. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D6E343418596]
Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas.
Stravodimou A., Voutsadakis I.A., 2022/02/24. World journal of clinical oncology, 13 (2) pp. 135-146. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_145ED5AE75A7]
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
Aedo-Lopez V., Gérard C.L., Boughdad S., Gautron Moura B., Berthod G., Digklia A., Homicsko K., Schaefer N., Duran R., Cuendet M.A. et al., 2022/02/24. Cancers, 14 (5) p. 1162. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F8308EFA619]
(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences.
Zander T., Wagner A.D., 2022/02/21. Cancers, 14 (4) p. 1088. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B420C71B37F7]
 
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
Passaro A., Brahmer J., Antonia S., Mok T., Peters S., 2022/02/20. Journal of clinical oncology, 40 (6) pp. 598-610. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4FF2DE2E645B]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
 
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo R.A., Han J.Y., Dafni U., Cho B.C., Yeo C.M., Nadal E., Carcereny E., de Castro J., Sala M.A., Bernabé R. et al., 2022/02. Annals of oncology, 33 (2) pp. 181-192. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6A6669A4204F]
 
Aggressive systemische Mastozytose mit erhöhter diffuser 18F-FDG-Aufnahme im Knochenmark [Aggressive systemic mastocytosis with diffuse bone marrow 18F-FDG uptake]
Koukalová R., Vašina J., Štika J., Doubek M., Szturz P., 2022/02. Nuklearmedizin. Nuclear medicine, 61 (1) pp. 58-61. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1CE439DEB48E]
 
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Budczies J., Kirchner M., Kluck K., Kazdal D., Glade J., Allgäuer M., Kriegsmann M., Heußel C.P., Herth F.J., Winter H. et al., 2022/02. Cancer immunology, immunotherapy, 71 (2) pp. 251-265. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0DB753CF82DB]
 
Erratum: Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies
Bajpai Jyoti, Mailankody Sharada, Garrido Pilar, Peters Solange, 2022/02. Indian Journal of Medical and Paediatric Oncology, 43 (01) pp. e1-e1.
[DOI][WoS][serval:BIB_C3B409B4C90A]
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
Gridelli C., Peters S., Mok T., Forde P.M., Reck M., Attili I., de Marinis F., 2022/02. ESMO open, 7 (1) p. 100355. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3AF0144EC613]
 
Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force.
Özdemir B.C., Oertelt-Prigione S., Adjei A.A., Borchmann S., Haanen J.B., Letsch A., Mir O., Quaas A., Verhoeven RHA, Wagner A.D., 2022/02. Annals of oncology, 33 (2) pp. 126-128. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_60480A3079B7]
 
Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies
Bajpai Jyoti, Mailankody Sharada, Garrido Pilar, Peters Solange, 2022/02. Indian Journal of Medical and Paediatric Oncology, 43 (01) pp. 004-007.
[DOI][WoS][serval:BIB_E5E72205B561]
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.
Sessa C., Cortes J., Conte P., Cardoso F., Choueiri T., Dummer R., Lorusso P., Ottmann O., Ryll B., Mok T. et al., 2022/02. ESMO open, 7 (1) p. 100339. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3E779B64CA41]
 
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile N.A., Messersmith H., Gatson N.T., Hottinger A.F., Lassman A., Morton J., Ney D., Nghiemphu P.L., Olar A., Olson J. et al., 2022/02/01. Journal of clinical oncology, 40 (4) pp. 403-426. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2B8FA515AE4E]
WHO-ESMO collaboration in cancer control: policies into action to save lives.
Mikkelsen B., Peters S., 2022/02. ESMO open, 7 (1) p. 100373. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_72D6021F3228]
Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.
Teixeira Farinha H., Digklia A., Schizas D., Demartines N., Schäfer M., Mantziari S., 2022/01/22. Cancers, 14 (3) p. 554. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B02180461EEC]
 
Targeting HER2-Mutant NSCLC - The Light Is On.
Passaro A., Peters S., 2022/01/20. The New England journal of medicine, 386 (3) pp. 286-289. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_934F0D17F639]
Neurologie [Neurology : what's new in 2021]
Vicino A., Allali G., Bally J., Castro Jimenez M., Chiabotti Salvioni P., Hirt L., Hottinger A., Michel P., Novy J., Pot Kreis C. et al., 2022/01/19. Revue medicale suisse, 18 (764-5) pp. 51-55. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A713627E7914]
The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience.
Bragina M.E., Daina A., Perez MAS, Michielin O., Zoete V., 2022/01/12. International journal of molecular sciences, 23 (2) p. 811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9174E37AD078]
SPICA: Swiss portal for immune cell analysis.
Andreatta M., David FPA, Iseli C., Guex N., Carmona S.J., 2022/01/07. Nucleic acids research, 50 (D1) pp. D1109-D1114. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1425D341196A]
Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients.
Papadopoulos S., Koulouris P., Royer-Chardon C., Tsoumakidou G., Dolcan A., Cherix S., Matter M., Omoumi P., Digklia A., 2022. Frontiers in endocrinology, 13 p. 794512. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F80FCDEF66D]
 
Consideration of sex and gender aspects in oncology: rationale, curent status, and perspectives
Wagner Anna, Oezdemir Berna, 2022. Italian Journal of Sex- and Gender-specific Medicine, 8 (1) pp. 55-58. Peer-reviewed.
[serval:BIB_5B967CA1C315]
 
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Peters S., Pujol J.L., Dafni U., Dómine M., Popat S., Reck M., Andrade J., Becker A., Moro-Sibilot D., Curioni-Fontecedro A. et al., 2022/01. Annals of oncology, 33 (1) pp. 67-79. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_82275164BC57]
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Michielin O., Lalani A.K., Robert C., Sharma P., Peters S., 2022/01. Journal for immunotherapy of cancer, 10 (1) pp. e003024. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8EB4E8449258]
 
Diagnostic surveillance of high-grade gliomas: towards automated change detection using radiology report classification
Di Noto Tommaso, Atat Chirine, Teiga Eduardo Gamito, Hegi Monika, Hottinger Andreas, Bach Cuadra Meritxell, Hagmann Patric, Richiardi Jonas, 2022/01/01. pp. 423-436 dans Machine Learning and Principles and Practice of Knowledge Discovery in Databases. ECML PKDD 2021., Communications in Computer and Information Science. Peer-reviewed, Springer, Cham.
[DOI][serval:BIB_4653B6A7BD8C]
Efficacy of Eribulin in Soft Tissue Sarcomas.
Phillips E., Jones R.L., Huang P., Digklia A., 2022. Frontiers in pharmacology, 13 p. 869754. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BAD5D07E845B]
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
Peters S., Galle P.R., Bernaards C.A., Ballinger M., Bruno R., Quarmby V., Ruppel J., Vilimovskij A., Wu B., Sternheim N. et al., 2022/01. Clinical and translational science, 15 (1) pp. 141-157. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_527DB42F25A1]
Gallbladder cancer during pregnancy treated with surgery and adjuvant gemcitabine: A case report and review of the literature.
Diciolla A., Gianoni M., Fleury M., Szturz P., Demartines N., Peters S., Duran R., Desseauve D., Panchaud M.A., Fasquelle F. et al., 2022. Frontiers in oncology, 12 p. 1006387. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83C6E9C8B673]
 
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee JVMG et al., 2022/01. Annals of oncology, 33 (1) pp. 20-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D7172015C17E]
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V., Kurt M., Zhang L., Butler M.O., Michielin O., Amadi A., Hernlund E., Johnson H.M., Kotapati S., Moshyk A. et al., 2022. MDM policy & practice, 7 (1) p. 23814683221089659. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0DDC4E311C75]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
Bandiera C., Pasquier J., Locatelli I., Niquille A., Wuerzner G., Dotta-Celio J., Hachfeld A., Wandeler G., Wagner A.D., Csajka C. et al., 2022. Patient preference and adherence, 16 pp. 2313-2320. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_813F43A545D0]
 
Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.
Mulvey A., Muggeo-Bertin E., Berthold D.R., Herrera F.G., 2022. Frontiers in immunology, 13 p. 859785. Peer-reviewed.
[DOI][Pmid][serval:BIB_DE34735C811E]
Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit.
Kalff M.C., Wagner A.D., Verhoeven RHA, Lemmens VEPP, van Laarhoven HWM, Gisbertz S.S., van Berge Henegouwen M.I., Dutch Upper GI Cancer Audit group, 2022/01. Gastric cancer, 25 (1) pp. 22-32. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3C125C4BB6B6]
Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study.
Pijnappel E.N., Schuurman M., Wagner A.D., de Vos-Geelen J., van der Geest LGM, de Groot J.B., Koerkamp B.G., de Hingh IHJT, Homs MYV, Creemers G.J. et al., 2022. Frontiers in oncology, 12 p. 839779. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A44EFB021E8D]
 
Structural Prediction of Peptide–MHC Binding Modes
Perez Marta A. S., Cuendet Michel A., Röhrig Ute F., Michielin Olivier, Zoete Vincent, 2022. pp. 245-282 dans Computational Peptide Science, Springer US.
[DOI][Pmid][serval:BIB_5B61FB9FCC6D]
Transfer learning with weak labels from radiology reports: application to glioma change detection
Di Noto Tommaso, Bach Cuadra Meritxell, Atat Chirine, Gamito Teiga Eduardo, Hegi Monika, Hottinger Andreas, Hagmann Patric, Richiardi Jonas, 2022..
[URN][DOI][serval:BIB_9CC85EE111CA]
2021
Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig U.F., Michielin O., Zoete V., 2021/12/23. Journal of medicinal chemistry, 64 (24) pp. 17690-17705. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_27218E957A69]
 
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
Dziadziuszko R., Mok T., Peters S., Han J.Y., Alatorre-Alexander J., Leighl N., Sriuranpong V., Pérol M., de Castro Junior G., Nadal E. et al., 2021/12. Journal of thoracic oncology, 16 (12) pp. 2040-2050. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6A6B08E8EC98]
 
Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.
Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S. et al., 2021/12. Annals of oncology, 32 (12) pp. 1520-1536. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6EB798E6C509]
 
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.
Schoenfeld A.J., Antonia S.J., Awad M.M., Felip E., Gainor J., Gettinger S.N., Hodi F.S., Johnson M.L., Leighl N.B., Lovly C.M. et al., 2021/12. Annals of oncology, 32 (12) pp. 1597-1607. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D6DEE26F8042]
 
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.
Desai A., Mohammed T.J., Duma N., Garassino M.C., Hicks L.K., Kuderer N.M., Lyman G.H., Mishra S., Pinato D.J., Rini B.I. et al., 2021/12/01. JAMA oncology, 7 (12) pp. 1882-1890. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5B7F58C6E972]
 
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.
Remon J., Soria J.C., Peters S., ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, 2021/12. Annals of oncology, 32 (12) pp. 1637-1642. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_38CABBD2FC4C]
Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.
Berghoff A.S., Sessa C., Yang J.C., Tsourti Z., Tsang J., Tabernero J., Peters S., Linardou H., Letsch A., Haanen J. et al., 2021/12. ESMO open, 6 (6) p. 100281. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_427B300443B4]
Infirmière clinicienne de centre du cancer : l’expérience du Centre de la prostate du CHUV [Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center]
Codeluppi C., Ninane F., Jolliet L., Glemarec P., Orcurto A., Rakauskas A., Tawadros T., Bosshard P., Eicher M., Herrera F. et al., 2021/12/01. Revue medicale suisse, 17 (761) pp. 2082-2085. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B3EF72B4777A]
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.
Keam B., Machiels J.P., Kim H.R., Licitra L., Golusinski W., Gregoire V., Lee Y.G., Belka C., Guo Y., Rajappa S.J. et al., 2021/12. ESMO open, 6 (6) p. 100309. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_225488014D1A]
 
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer.
Yoshino T., Argilés G., Oki E., Martinelli E., Taniguchi H., Arnold D., Mishima S., Li Y., Smruti B.K., Ahn J.B. et al., 2021/12. Annals of oncology, 32 (12) pp. 1496-1510. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0E76CBC7CD04]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.
Kanesvaran R., Porta C., Wong A., Powles T., Ng Q.S., Schmidinger M., Ye D., Malhotra H., Miura Y., Lee J.L. et al., 2021/12. ESMO open, 6 (6) p. 100304. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83EBCC2DD97D]
 
Early discharge after thoracoscopic anatomical pulmonary resection for non-small-cell lung cancer.
Forster C., Perentes J.Y., Ojanguren A., Abdelnour-Berchtold E., Zellweger M., Bouchaab H., Peters S., Krueger T., Gonzalez M., 2021/11/22. Interactive cardiovascular and thoracic surgery, 33 (6) pp. 892-898. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E6AB61794067]
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Harari A., Sarivalasis A., de Jonge K., Thierry A.C., Huber F., Boudousquie C., Rossier L., Orcurto A., Imbimbo M., Baumgaertner P. et al., 2021/11/18. Cancers, 13 (22) p. 5801. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A292F2251A7]
Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study.
Dijksterhuis WPM, Kalff M.C., Wagner A.D., Verhoeven RHA, Lemmens VEPP, van Oijen MGH, Gisbertz S.S., van Berge Henegouwen M.I., van Laarhoven HWM, 2021/11/02. Journal of the National Cancer Institute, 113 (11) pp. 1551-1560. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_949817C75DEC]
 
MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Frappaz D., Barritault M., Montané L., Laigle-Donadey F., Chinot O., Le Rhun E., Bonneville-Levard A., Hottinger A.F., Meyronnet D., Bidaux A.S. et al., 2021/11/02. Neuro-oncology, 23 (11) pp. 1949-1960. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBD0E5E6E601]
 
Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G., Yong C.H., Herrera Gómez R.G., 2021/11. Critical reviews in oncology/hematology, 167 p. 103503. Peer-reviewed.
[DOI][Pmid][serval:BIB_47306AD1185D]
 
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Peters S., Danson S., Ejedepang D., Dafni U., Hasan B., Radcliffe H.S., Bustin F., Crequit J., Coate L., Guillot M. et al., 2021/11. Lung cancer, 161 pp. 76-85. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_213E1391F9A7]
 
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.
Le Rhun E., Guckenberger M., Smits M., Dummer R., Bachelot T., Sahm F., Galldiks N., de Azambuja E., Berghoff A.S., Metellus P. et al., 2021/11. Annals of oncology, 32 (11) pp. 1332-1347. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_689733AC5486]
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D., Degrauwe N., Michielin O., Monney P., Özdemir B.C., 2021/11. Cancer treatment reviews, 100 p. 102282. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_63661F460346]
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study.
Da Silva Lopes A.M., Colomer-Lahiguera S., Mederos Alfonso N., Aedo-Lopez V., Spurrier-Bernard G., Tolstrup L.K., Pappot H., Aspeslagh S., Rogiers A., Neyns B. et al., 2021/11. European journal of cancer, 157 pp. 225-237. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5AEE20D374F]
 
Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes.
Szturz P., Vermorken J.B., 2021/11. The oncologist, 26 (11) pp. 899-901. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_76CC0689FF16]
 
Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.
Gronchi A., Miah A.B., Dei Tos A.P., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S. et al., 2021/11. Annals of oncology, 32 (11) pp. 1348-1365. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_978E5DF3EB7B]
Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.
Vuong D., Bogowicz M., Wee L., Riesterer O., Vlaskou Badra E., D'Cruz L.A., Balermpas P., van Timmeren J.E., Burgermeister S., Dekker A. et al., 2021/10/22. Scientific reports, 11 (1) p. 20890. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B2FF32E1158E]
 
213 Genomic alteration of a metastatic gastric-type cervical adenocarcinoma: hints and personalized treatment options
Sarivalasis A, Bisig B, Hastir D, Lefort K, Liapi A, 2021/10. pp. A300 dans Pathology, BMJ Publishing Group Ltd.
[DOI][WoS][serval:BIB_EB50AFBF675C]
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S., Latifyan S., Fenwick C., Bouchaab H., Suffiotti M., Moslehi J.J., Salem J.E., Schaefer N., Nicod-Lalonde M., Costes J. et al., 2021/10. Journal for immunotherapy of cancer, 9 (10) pp. e003594. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6D88B7F593BA]
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.
Castelo-Branco L., Awada A., Pentheroudakis G., Perez-Gracia J.L., Mateo J., Curigliano G., Banerjee S., Giuliani R., Lordick F., Cervantes A. et al., 2021/10. ESMO open, 6 (5) p. 100237. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4A3F20502CAC]
Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians.
Chazan G., Franchini F., Alexander M., Banerjee S., Mileshkin L., Blinman P., Zielinski R., Karikios D., Pavlakis N., Peters S. et al., 2021/10. ESMO open, 6 (5) p. 100224. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C2A577E9F0A6]
Is sleeve lobectomy safe after induction therapy?-a systematic review and meta-analysis.
Chriqui L.E., Forster C., Lovis A., Bouchaab H., Krueger T., Perentes J.Y., Gonzalez M., 2021/10. Journal of thoracic disease, 13 (10) pp. 5887-5898. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC8BE5624D74]
 
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Szturz P., Vinches M., Remenár É., van Herpen CML, Abdeddaim C., Stewart J.S., Fortpied C., Vermorken J.B., 2021/10. European journal of cancer, 156 pp. 109-118. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C29FF4897B51]
 
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers M.L., Dimitriou F., Lau P., Bhave P., McArthur G.A., Zimmer L., Kudura K., Gérard C.L., Levesque M.P., Michielin O. et al., 2021/10. European journal of cancer, 156 pp. 149-163. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A82FBE1EAA00]
The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.
Li A., Kuderer N.M., Hsu C.Y., Shyr Y., Warner J.L., Shah D.P., Kumar V., Shah S., Kulkarni A.A., Fu J. et al., 2021/10. Journal of thrombosis and haemostasis, 19 (10) pp. 2522-2532. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2EAD54EA1A35]
Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey.
Adam K.M., Osthoff M., Lamoth F., Conen A., Erard V., Boggian K., Schreiber P.W., Zimmerli S., Bochud P.Y., Neofytos D. et al., 2021/10. Open forum infectious diseases, 8 (10) pp. ofab471. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E1C2CA5BE723]
A Locally Advanced Endometrioid Adenocarcinoma Arising from Vaginal Endometriosis: Management and Review of the Literature
Costanza M., Herrera F.G., Hastir D., Mathevet P., Sarivalasis A., 2021/09/17. Reports, 4 (3) p. 29. Peer-reviewed.
[URN][DOI][WoS][serval:BIB_47314A3E8C85]
 
Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets.
Ioannidou E., Moschetta M., Shah S., Parker J.S., Ozturk M.A., Pappas-Gogos G., Sheriff M., Rassy E., Boussios S., 2021/09/14. International journal of molecular sciences, 22 (18) p. 9926. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3CFEA4E724AA]
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.
Chiang C.L., Rovelli R., Sarivalasis A., Kandalaft L.E., 2021/09/10. Cancers, 13 (18) p. 4553. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0968A9F9CD4C]
 
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild S.I., Zippelius A., Eboulet E.I., Savic Prince S., Betticher D., Bettini A., Früh M., Joerger M., Lardinois D., Gelpke H. et al., 2021/09/10. Journal of clinical oncology, 39 (26) pp. 2872-2880. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9646C9E25D4B]
Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis: Review of Published Cases.
Roukain A., La Rosa S., Bongiovanni M., Nicod Lalonde M., Cristina V., Montemurro M., Cochet S., Luquain A., Kopp P.A., Sykiotis G.P., 2021/09/06. Cancers, 13 (17) p. 4482. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E774E4C20ED0]
 
1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study
Lopes A.M.D.S., Colomer-Lahiguera S., Mederos-Alfonso N-N., Lopez V. Aedo, Spurrier-Bernard G., Tolstrup L.K., Pappot H., Aspeslagh S., Rogiers A., Neyns B. et al., 2021/09., ESMO Congress 2021 pp. S1180 dans Annals of Oncology.
[DOI][WoS][serval:BIB_8EB95DA9992D]
A new method to visualize and to spare the ureters during SBRT for oligo metastatic patients.
Muggeo-Bertin E., Moeckli R., Vallet V., Berthold D., Godin S., Bourhis J., Herrera F.G., 2021/09. Technical innovations & patient support in radiation oncology, 19 pp. 7-10. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5205796889DB]
 
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer.
Schettini F., Giuliano M., Lambertini M., Bartsch R., Pinato D.J., Onesti C.E., Harbeck N., Lüftner D., Rottey S., van Dam P.A. et al., 2021/09/01. Cancers, 13 (17) p. 4421. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D8F571D2AE12]
 
CN44 Exploring cancer patients' and survivors' experiences of cancer care in COVID-19: A longitudinal qualitative study
Dowling M., Drury A., Eicher M., 2021/09., ESMO Congress 2021 pp. S1272 dans Annals of Oncology, Elsevier BV.
[DOI][WoS][serval:BIB_6BD11A8B1425]
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group.
Koessler T., Alsina M., Arnold D., Ben-Aharon I., Lutz M.P., Obermannova R., Peeters M., Sclafani F., Smyth E., Valle J.W. et al., 2021/09. British journal of cancer, 125 (7) pp. 911-919. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9EA83BC830BF]
 
Imaging Features of Pulmonary Immune-related Adverse Events.
Pozzessere C., Lazor R., Jumeau R., Peters S., Prior J.O., Beigelman-Aubry C., 2021/09. Journal of thoracic oncology, 16 (9) pp. 1449-1460. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_42CE5369FFE3]
 
LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Banerjee S., Ottevanger P.B., Sarivalasis A., Le Scodan R., Montes A., Kroep J.R., Romeo Marin M., Casado Herraez A., Auvray-Kuentz M., Westermann A.M. et al., 2021/09. Annals of Oncology, 32 pp. S1308.
[DOI][WoS][serval:BIB_AA7296087B5B]
Swiss germ-cell cancer consensus recommendations.
Beyer J., Berthold D., Bode P.K., Cathomas R., Fankhauser C.D., Fischer S., Gillessen S., Gross T., Hermanns T., Honecker F. et al., 2021/08/23. Swiss medical weekly, 151 (33-34) pp. w30023. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_632D6763E6AD]
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging.
Oliveira C., Amstutz F., Vuong D., Bogowicz M., Hüllner M., Foerster R., Basler L., Schröder C., Eboulet E.I., Pless M. et al., 2021/08/21. EJNMMI research, 11 (1) p. 79. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A190AD7F0236]
Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice.
Cudalbu C., Bady P., Lai M., Xin L., Gusyatiner O., Hamou M.F., Lepore M., Brouland J.P., Daniel R.T., Hottinger A.F. et al., 2021/08/04. Acta neuropathologica communications, 9 (1) p. 133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB8B36AE633E]
Acute cardiac manifestations under immune checkpoint inhibitors-beware of the obvious: a case report.
Arangalage D., Pavon A.G., Özdemir B.C., Michielin O., Schwitter J., Monney P., 2021/08. European heart journal. Case reports, 5 (8) pp. ytab262. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E2AAE474DB65]
 
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
da Silva I.P., Ahmed T., Reijers ILM, Warner A.B., Patrinely J.R., Serra-Bellver P., Allayous C., Mangana J., Zimmer L., Trojaniello C. et al., 2021/08. The Lancet. Oncology, 22 (8) pp. e343-e344. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D51407044D20]
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.
Thouvenin L., Charrier M., Clement S., Christinat Y., Tille J.C., Frigeri M., Homicsko K., Michielin O., Bodmer A., Chappuis P.O. et al., 2021/08. Gynecologic oncology reports, 37 p. 100787. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB2F51C1A9EA]
 
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
Hepner A., Atkinson V.G., Larkin J., Burrell R.A., Carlino M.S., Johnson D.B., Zimmer L., Tsai K.K., Klein O., Lo S.N. et al., 2021/08. European journal of cancer, 153 pp. 213-222. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1A7F34C37268]
 
Slowness Predicts Mortality: A Comparative Analysis of Walking Speed and Moberg Picking-Up Tests.
Meyer M.L., Fustinoni S., Henchoz Y., Hottinger A.F., Santos-Eggimann B., 2021/08. Journal of the American Medical Directors Association, 22 (8) pp. 1652-1657.e2. Peer-reviewed.
[DOI][Pmid][serval:BIB_C9E6961F8997]
Immunotherapy in Glioblastoma: A Clinical Perspective.
Desbaillets N., Hottinger A.F., 2021/07/24. Cancers, 13 (15) p. 3721. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_89F18E1BB4ED]
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation.
Maio M., Lahn M., Di Giacomo A.M., Covre A., Calabrò L., Ibrahim R., Fox B., Siena Think Tank, 2021/07/23. Journal of experimental & clinical cancer research, 40 (1) p. 240. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E27207EDCAD2]
 
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Haas L., Elewaut A., Gerard C.L., Umkehrer C., Leiendecker L., Pedersen M., Krecioch I., Hoffmann D., Novatchkova M., Kuttke M. et al., 2021/07. Nature cancer, 2 (7) pp. 693-708. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_630A38C698EC]
Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Rakauskas A., Tawadros T., Lucca I., Herrera F., Bourhis J., Burruni R., Gomes M.N., Codeluppi C., Jolliet L., La Rosa S. et al., 2021/07. Investigative and clinical urology, 62 (4) pp. 416-422. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_11DA8B398364]
 
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen C.N., Bai X., Quah T., Lo S.N., Allayous C., Callaghan S., Martínez-Vila C., Wallace R., Bhave P., Reijers ILM et al., 2021/07. Annals of oncology, 32 (7) pp. 917-925. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4024F0C5F587]
 
ESMO pays tribute to Professor José Baselga.
Peters S., Tabernero J., Cervantes A., Banerjee S., Giuliani R., Lordick F., 2021/07. Annals of oncology, 32 (7) pp. 823-824. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AB7BDD49CD7C]
Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice
Cudalbu C., Bady P., Lai M., Xin L., Gusyatiner O., Hamou MF, Lepore M., Brouland JP, Daniel RT, Hottinger AF et al., 2021/07/01..
[URN][DOI][serval:BIB_62503BCD223C]
Neutrophils in the era of immune checkpoint blockade.
Faget J., Peters S., Quantin X., Meylan E., Bonnefoy N., 2021/07. Journal for immunotherapy of cancer, 9 (7) pp. e002242. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4BDDB5E5C55B]
 
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Garon E.B., Cho B.C., Reinmuth N., Lee K.H., Luft A., Ahn M.J., Robinet G., Le Moulec S., Natale R., Schneider J. et al., 2021/07. Clinical lung cancer, 22 (4) pp. 301-312.e8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_29D565681F08]
 
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.
Dingemans A.C., Früh M., Ardizzoni A., Besse B., Faivre-Finn C., Hendriks L.E., Lantuejoul S., Peters S., Reguart N., Rudin C.M. et al., 2021/07. Annals of oncology, 32 (7) pp. 839-853. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E3B6947CE94F]
 
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Soo R., Han J-Y., Dimopoulou G., Cho B.C., Yeo C.M., Nadal E., Carcereny E., de Castro J., Sala M.A., Bernabe R. et al., 2021/07. Annals of Oncology, 32 (7) pp. 942-944.
[DOI][WoS][serval:BIB_E123EA0B584E]
Prise en charge des sarcomes des tissus mous abdominaux [Management of abdominal soft tissue sarcomas]
Djafarrian R., Zingg T., Digklia A., Becce F., Özsahin E.M., La Rosa S., Demartines N., Matter M., 2021/06/16. Revue medicale suisse, 17 (743) pp. 1172-1176. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B1CF53F8316E]
Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity.
Garofalo M., Piccoli L., Romeo M., Barzago M.M., Ravasio S., Foglierini M., Matkovic M., Sgrignani J., De Gasparo R., Prunotto M. et al., 2021/06/10. Nature communications, 12 (1) p. 3532. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8025CE5AB3D3]
Diabète secondaire aux nouvelles thérapies ciblées contre le cancer [New-onset diabetes and novel targeted therapies against cancer]
Zordan A., Kosinski C., Zaman K., Wojtusciszyn A., 2021/06/02. Revue medicale suisse, 17 (741) pp. 1067-1071. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F6604A18413C]
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Grivas P., Khaki A.R., Wise-Draper T.M., French B., Hennessy C., Hsu C.Y., Shyr Y., Li X., Choueiri T.K., Painter C.A. et al., 2021/06. Annals of oncology, 32 (6) pp. 787-800. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A7A24C418B5A]
 
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype.
Kokkali S., Stravodimou A., Duran-Moreno J., Koufopoulos N., Voutsadakis I.A., Digklia A., 2021/06. Expert review of anticancer therapy, 21 (6) pp. 591-604. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A06BD9846D13]
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.
Stacchiotti S., Miah A.B., Frezza A.M., Messiou C., Morosi C., Caraceni A., Antonescu C.R., Bajpai J., Baldini E., Bauer S. et al., 2021/06. ESMO open, 6 (3) p. 100170. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9176DFAEB6D9]
ESMO pays tribute to Professor José Baselga.
Peters S., Tabernero J., Cervantes A., Banerjee S., Giuliani R., Lordick F., 2021/06. ESMO open, 6 (3) p. 100130. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D5A244B4A45D]
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey.
Garrido P., Adjei A.A., Bajpai J., Banerjee S., Berghoff A.S., Choo S.P., Felip E., Furness AJS, Garralda E., Haanen J. et al., 2021/06. ESMO open, 6 (3) p. 100131. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CAF2BC9777BE]
 
Invasive Breast Cancer in a Trans Man After Bilateral Mastectomy: Case Report and Literature Review.
Kopetti C., Schaffer C., Zaman K., Liapi A., di Summa P.G., Bauquis O., 2021/06. Clinical breast cancer, 21 (3) pp. e154-e157. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AC57C6EFDDE7]
 
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I., Ahmed T., Reijers ILM, Weppler A.M., Betof Warner A., Patrinely J.R., Serra-Bellver P., Allayous C., Mangana J., Nguyen K. et al., 2021/06. The Lancet. Oncology, 22 (6) pp. 836-847. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_001DC1DD3B64]
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression.
Tavernari D., Battistello E., Dheilly E., Petruzzella A.S., Mina M., Sordet-Dessimoz J., Peters S., Krueger T., Gfeller D., Riggi N. et al., 2021/06. Cancer discovery, 11 (6) pp. 1490-1507. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F6D4BAEDCE1E]
 
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
Finn S.P., Addeo A., Dafni U., Thunnissen E., Bubendorf L., Madsen L.B., Biernat W., Verbeken E., Hernandez-Losa J., Marchetti A. et al., 2021/06. Journal of thoracic oncology, 16 (6) pp. 990-1002. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13B0DD5F94DD]
 
Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic.
Labaki C., Peters S., Choueiri T.K., 2021/06. Cancer discovery, 11 (6) pp. 1330-1335. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A12F230673D5]
Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond.
Szturz P., Vermorken J.B., 2021/05/21. Cancers, 13 (11) p. 2518. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DDEE5B1D0575]
Cancer du sein chez la femme en [Breast cancer during pregnancy]
Schnetz M., Stravodimou A., Cisarovsky C., Dunand A., Prior J.O., Nicod Lalonde M., Baud D., Meuwly J.Y., Winterfeld U., Zaman K., 2021/05/19. Revue medicale suisse, 17 (739) pp. 957-961. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_80DEB9D1E4CC]
Carcinome anaplasique de la thyroïde : nouvelles approches thérapeutiques [Anaplastic thyroid carcinoma : new therapeutic approaches]
Stamatiou A., Herrera-Gómez R.G., Szturz P., Bisig B., Romano E., Sykiotis G., Gorostidi F., La Rosa S., Kopp P., Cristina V., 2021/05/19. Revue medicale suisse, 17 (739) pp. 962-966. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E0FB351F6891]
Immunothérapie dans le cancer de la vessie : mise à jour 2021 [Immunotherapy for bladder cancer in 2021]
Cisarovsky C., Latifyan S., Perrinjaquet C., Berthold D., Orcurto A., 2021/05/19. Revue medicale suisse, 17 (739) pp. 974-977. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_954186CA59D9]
Oncologie et pandémie de Covid-19 : les patients au cœur des enjeux.
Dietrich P.Y., Aapro M., Peters S., 2021/05/19. Revue medicale suisse, 17 (739) p. 955. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_ECB4219DB1D9]
 
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM).
Hofer S., Keller K., Imbach L., Roelcke U., Hutter G., Thomas H., Hertler C., Le Rhun E., Vasella F., Cordier D. et al., 2021/05/10. Swiss medical weekly, 151 pp. w20501. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ADD1B8BB43E3]
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Klein M., Drijver A.J., van den Bent M.J., Bromberg J.C., Hoang-Xuan K., Taphoorn MJB, Reijneveld J.C., Ben Hassel M., Vauleon E., Eekers DBP et al., 2021/05/05. Neuro-oncology, 23 (5) pp. 803-811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_26325EFBDC53]
Cystathionine-gamma-lyase overexpression in T cells enhances antitumor effect independently of cysteine autonomy.
Lancien M., Gueno L., Salle S., Merieau E., Beriou G., Nguyen T.H., Abidi A., Dilek N., Solomon P., Poschmann J. et al., 2021/05. Cancer science, 112 (5) pp. 1723-1734. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_145E54BFE34D]
 
GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy.
Ancey P.B., Contat C., Boivin G., Sabatino S., Pascual J., Zangger N., Perentes J.Y., Peters S., Abel E.D., Kirsch D.G. et al., 2021/05/01. Cancer research, 81 (9) pp. 2345-2357. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A171D8D09919]
 
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Felip E., Shaw A.T., Bearz A., Camidge D.R., Solomon B.J., Bauman J.R., Bauer T.M., Peters S., Toffalorio F., Abbattista A. et al., 2021/05. Annals of oncology, 32 (5) pp. 620-630. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_37A8F854B2F7]
 
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E., Wicky A., Bouchaab H., Imbimbo M., Delyon J., Gautron Moura B., Gérard C.L., Latifyan S., Özdemir B.C., Caikovski M. et al., 2021/05. European journal of cancer, 149 pp. 153-164. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4791AD7F437D]
 
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
Passaro A., Mok T., Peters S., Popat S., Ahn M.J., de Marinis F., 2021/05. Journal of thoracic oncology, 16 (5) pp. 764-773. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C53093BF243E]
 
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331<sup>☆</sup>.
Spigel D.R., Vicente D., Ciuleanu T.E., Gettinger S., Peters S., Horn L., Audigier-Valette C., Pardo Aranda N., Juan-Vidal O., Cheng Y. et al., 2021/05. Annals of oncology, 32 (5) pp. 631-641. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4545F4DBDC90]
Stereotactic lung reirradiation for local relapse: A case series.
Kinj R., Casutt A., Bennassi A., Bouchaab H., Vallet V., Lovis A., Ozsahin M., 2021/05. Clinical and translational radiation oncology, 28 pp. 85-87. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_306A219BD9DC]
 
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
Dimitriou F., Zaremba A., Allayous C., Kähler K.C., Gerard C.L., Festino L., Schäfer S., Toussaint F., Heinzerling L., Hassel J.C. et al., 2021/05. European journal of cancer, 149 pp. 37-48. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDCE3AC07754]
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate.
Garassino M.C., Vyas M., de Vries EGE, Kanesvaran R., Giuliani R., Peters S., European Society for Medical Oncology, 2021/05. Annals of oncology, 32 (5) pp. 579-581. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AF4BDC63F4F5]
 
Treatment landscape of metastatic pancreatic cancer.
De Dosso S., Siebenhüner A.R., Winder T., Meisel A., Fritsch R., Astaras C., Szturz P., Borner M., 2021/05. Cancer treatment reviews, 96 p. 102180. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_55A027525A9C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University